{"id":5142,"date":"2014-07-29T09:00:00","date_gmt":"2014-07-29T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/"},"modified":"2024-09-23T11:22:41","modified_gmt":"2024-09-23T11:22:41","slug":"vooruitgang-op-het-gebied-van-inkapseling","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/","title":{"rendered":"Vooruitgang op het gebied van inkapseling"},"content":{"rendered":"<p>Het Amerikaanse bedrijf ViaCyte heeft goedkeuring van de Amerikaanse Food and Drug Administration om hun therapie voor inkapseling te testen. ViaCyte ontwikkelt deze therapie met financi\u00eble steun van Breakthrough T1D.<\/p>\n<p>De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesystee<span class=\"text_exposed_show\">m insuline kunnen afgeven. Ook ontwikkelde ViaCyte het afgiftesysteem, genaamd Encaptra. Ook dit is inmiddels goedgekeurd door de FDA.<br \/><\/span><\/p>\n<p><span class=\"text_exposed_show\"><\/span><span class=\"text_exposed_show\"><\/span>Als de beide onderdelen goed door alle testen komen, zou dat in de toekomst betekenen dat mensen met type 1 diabetes niet langer afhankelijk zijn van externe insuline. Het afgiftesysteem kan dan in het lichaam ge\u00efmplanteerd worden. Daar geeft de therapie insuline af wanneer dit nodig is. <br \/><\/p>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Het Amerikaanse bedrijf ViaCyte heeft goedkeuring van de Amerikaanse Food and Drug Administration om hun therapie voor inkapseling te testen. ViaCyte ontwikkelt deze therapie met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem insuline kunnen afgeven. Ook ontwikkelde ViaCyte het afgiftesysteem, genaamd Encaptra. Ook dit [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,187,196,188],"tags":[],"class_list":["post-5142","post","type-post","status-publish","format-standard","hentry","category-archief","category-behandelen","category-betacelvervanging","category-genezen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vooruitgang op het gebied van inkapseling - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vooruitgang op het gebied van inkapseling - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Het Amerikaanse bedrijf ViaCyte heeft goedkeuring van de Amerikaanse Food and Drug Administration om hun therapie voor inkapseling te testen. ViaCyte ontwikkelt deze therapie met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem insuline kunnen afgeven. Ook ontwikkelde ViaCyte het afgiftesysteem, genaamd Encaptra. Ook dit [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-29T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:41+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Vooruitgang op het gebied van inkapseling\",\"datePublished\":\"2014-07-29T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\"},\"wordCount\":116,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\",\"Behandelen\",\"B\u00e8tacelvervanging\",\"Genezen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\",\"name\":\"Vooruitgang op het gebied van inkapseling - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2014-07-29T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vooruitgang op het gebied van inkapseling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vooruitgang op het gebied van inkapseling - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/","og_locale":"nl_NL","og_type":"article","og_title":"Vooruitgang op het gebied van inkapseling - Breakthrough T1D","og_description":"Het Amerikaanse bedrijf ViaCyte heeft goedkeuring van de Amerikaanse Food and Drug Administration om hun therapie voor inkapseling te testen. ViaCyte ontwikkelt deze therapie met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem insuline kunnen afgeven. Ook ontwikkelde ViaCyte het afgiftesysteem, genaamd Encaptra. Ook dit [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-07-29T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:41+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Vooruitgang op het gebied van inkapseling","datePublished":"2014-07-29T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/"},"wordCount":116,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Behandelen","B\u00e8tacelvervanging","Genezen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/","name":"Vooruitgang op het gebied van inkapseling - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2014-07-29T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/vooruitgang-op-het-gebied-van-inkapseling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Vooruitgang op het gebied van inkapseling"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5142"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5142\/revisions"}],"predecessor-version":[{"id":7193,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5142\/revisions\/7193"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}